早期的微观结构变化在左下面的前后筋:可能的阿尔茨海默氏症的关键因素 缓慢步行速度的阿尔茨海默病患者
Shan-Wen Liu1, Lin-Lin Yao1, Fang-Bo Li1
1Department of Neurology, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Brain and behavior
|March 13, 2026
概括
左下面前后囊 (IFOF_L) 的微观结构完整性与阿尔茨海默病 (AD) 患者的认知和运动缺陷有关,这些患者的步行速度缓慢. IFOF_L的恶化与步态障碍和认知障碍相关.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 医疗成像医学成像
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病.
- 步行速度和认知功能是AD进展的已知指标.
- 基于Fixel的分析 (FBA) 提供了对白质微观结构的先进见解.
研究的目的:
- 调查白质 (WM) 纤维通道变化与阿兹海默病患者的步行速度/认知功能之间的关联.
- 使用FBA进行与临床症状相关的WM完整性的详细分析.
主要方法:
- 对比26名可能患有慢步速度的AD患者 (AD-SGS),28名没有慢步速度的AD患者 (AD-nSGS) 和28名正常对照 (NC).
- 使用FBA来评估白质 (WM) 纤维密度 (FD),横截面积 (FC),密度和横截面积 (FDC).
- 相关联的WM纤维指标与神经心理测试得分和6米步行速度,经过调整年龄和性别后.
主要成果:
- 与AD-nSGS相比,AD-SGS组在左下面的前后囊 (IFOF_L) 中显著减少了FD和FDC.
- 在AD患者中,IFOF_L FDC与全球认知,注意力,执行功能,视觉空间功能和处理速度正相关.
- IFOF_L FD与6米步行速度正相关.
结论:
- IFOF_L的微结构完整性与慢步阿兹海默症患者的认知衰退和运动缺陷密切相关.
- IFOF_L的结构性恶化与阿尔茨海默氏症中行走障碍和认知障碍之间的相互作用有关.
更多相关视频
相关概念视频
Alzheimer's Disease: Overview
1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K


